Pfizer's 2022 sales top $100 billion but end to COVID-19 bonanza imminent
US drugmaker Pfizer (NYSE: PFE) cemented its place at the top of the pile of global pharma companies in delivering its 2022 financial results.
The firm reported an eye-watering annual revenue figure of $100.3 billion, a 23% rise on 2021’s total and a record for the industry. Quarterly sales were $24.29 billion, a more modest 2% increase, reflecting a slowing down of sales of COVID-19 products that is likely to continue. The fourth quarter figure missed the FactSet consensus of $24.38 billion.
Symbolic of just how much Pfizer has made from its COVID-19 products is the stat that, without the Paxlovid (nirmatrelvir/ritonavir) antiviral and Comirnaty vaccine sales, annual revenues grew by only 2%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze